Tildrakizumab Improves Wellbeing, Quality of Life for Psoriasis Patients
Long-term, real-world data show the IL-23 inhibitor benefits patient-reported measures of psychological wellbeing.
Dupilumab Quickly, Significantly Improves Sleep Quality in Atopic Dermatitis Patients
New data show adults receiving the biologic for eczema may see improvements in sleep disturbance within 4 weeks.
Rajani Katta, MD: Psoriasis, Other Dermatologic Conditions Connected to Obesity
An interview with Dr. Katta on her SDPA 2022 presentation, in which she covers the topic of obesity and its relationship to skin conditions such as plaque psoriasis.
SDPA 2022 Presentation Highlights: Dermatologic Conditions with Skin Depigmentation Resembling Vitiligo
In one of his SDPA 2022 presentations, Dr. Rosen spoke on different dermatological conditions with vitiligo-like presentations.
Dupilumab Rapidly, Significantly Improves Eczema Rashes, Itching in Infants, Toddlers
Phase 3 data suggest children aged <6 months to 5 years old have benefit in itch relief and skin clearance as soon as 1 week into systemic therapy regimens.
SDPA 2022 Presentation Highlights: Psoriasis Primer, Upcoming Biologic Therapies
During her SDPA 2022 presentation, Cynthia Trickett explored the topic of psoriasis, including comorbidities and treatment options.
Tralokinumab Provides Atopic Dermatitis Symptom, Severity and Quality of Life Benefit at 16 Weeks
New data from ECZTRA 1 and 2 show patients unable to achieve complete skin clearance nonetheless benefitted in at least 1 component of disease improvement.
Jennifer Orozco, DMSc, PA-C: Key Points from Presentation on ‘PAs Go Beyond’ Campaign
An interview on several major highlights from Dr. Orozsco’s presentation about the greater visibility and importance of physician associates at SDPA 2022.
Jennifer Orozco, DMSc, PA-C: Raising Awareness on Importance of Physician Associates in the Medical Workforce
An interview with Dr. Orozco regarding her presentation at SDPA 2022 on the topic of physician associates and their value in the modern medical system.
Robert Kirsner MD, PhD: Gaps in Knowledge on Wound Care in Dermatology Field
An SDPA 2022 interview with Dr. Robert Kirsner regarding his presentation regarding the topic of wound healing and related changes in the field.
Robert Kirsner MD, PhD: Presentation Highlights from ‘Healing the Unhealable Wound’
An interview at the SDPA 2022 Conference on major talking points from Dr. Robert Kirsner’s presentation on wound care with dermatologists and physician associates.
Robert Kirsner MD, PhD: Gaps in Knowledge on Wound Care in the Dermatology Field
An interview from SDPA 2022 regarding highlights from Dr. Robert Kirsner’s presentation on dermatologists and wound healing.
The Adequate Evaluation Teams, Treatment Plans for Stevens-Johnson Syndrome
Travis Vandergriff, MD, discusses the unique collaboration with ophthalmologists and urologists in the rare skin condition.
Tapinarof Cream Benefits Psoriasis Regardless of Baseline Disease Severity, Duration
An analysis of PSOARING 1 and 2 data show the topical therapy is efficacious across a wide spectrum of psoriatic disease and patient demographics.
Guselkumab Linked to Improved Psoriasis Treatment Continuation, Remission
An analysis suggests patients on the biologic fared better with adherence and outcomes than those on competitors including adalimumab.
The Signs and Symptoms of Stevens-Johnson Syndrome
A dive into the manifestation of the rare skin condition, and the impactful role of dermatologists in diagnosing it early.
Encapsulated Benzoyl Peroxide Cream, Tretinoin Combination Effectively & Safely Treats Acne
New phase 3 data show a microencapsulated form of the topical antiseptic and vitamin D derivative is beneficial and tolerable over 12 weeks.
The Pitfalls, Benefits of Influencing Dermatology Social Media
Savanna Perry, PA-C, discussed the challenge of standing out over influencers and estheticians regarding clinical dermatology insight, and the unique offerings of different platforms.
Tralokinumab Benefits Adolescent Eczema Patient-Reported Outcomes at 16 Weeks
New data from ECZTRA 6 show improved sleep quality, itch relief and quality of life among teenagers treating atopic dermatitis with the IL-13 inhibitor.
Atopic Dermatitis Patients Prefer Skin Clearance Outcomes, Topical Therapy
Results from a cross-sectional survey suggest consistent patient preferences for treatment outcomes and means of administration.
The Benefits & Challenges of Social Media Healthcare
Savanna Perry, PA-C, founder of The PA Platform, discusses the strategies and goals that go into building an online audience as a healthcare professional.
Roflumilast Cream Remains Effective, Tolerable for Plaque Psoriasis Over 24-Week Open-Label Extension
New phase 3 extension data show the topical PDE-4 inhibitor provided skin clearance to a significant rate of patients with psoriasis.
